Naobios, Nuvonis, and EVI Join Forces for Influenza Vaccine Innovation

Naobios, a contract development and manufacturing organisation, has entered into a collaborative agreement with biotechnology firm Nuvonis and the European Vaccine Initiative (EVI) to advance the development of a Human Viral Challenge Agent for influenza A(H3N2). This partnership is part of the Inno4Vac consortium’s initiative aimed at enhancing the efficiency of seasonal influenza vaccine development.

The project seeks to establish a Controlled Human Infection Model (CHIM) for influenza A(H3N2). This model will allow for healthy adult volunteers to be exposed to a well-characterised virus under clinical conditions, facilitating the collection of valuable data regarding vaccine efficacy and immune response. The need for this advancement arises from the ongoing public health challenge posed by seasonal influenza, which necessitates faster and more effective vaccine development processes.

Naobios will spearhead the Good Manufacturing Practice (GMP) production of the Human Viral Challenge Agent, utilising Nuvonis’s GMP Vero Working Cell Bank. This method is expected to streamline the manufacturing process by negating the requirement for additional cell bank development, thereby accelerating timelines and reducing associated risks and costs. Vero cells are widely accepted by regulatory authorities, including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

According to Christina Nicolodi, CEO of Nuvonis, “Our GMP Vero Working Cell Bank will play a crucial role in accelerating the GMP manufacturing process by eliminating the need for time-consuming cell bank production.” This strategic decision highlights the importance of efficiency in the vaccine development lifecycle.

Naobios has a proven track record in the field, having successfully delivered over 30 GMP batches of Human Viral Challenge Agents. This includes their previous work on a Respiratory Syncytial Virus (RSV) challenge agent in collaboration with Inno4Vac. The new influenza project not only strengthens Naobios’s ongoing partnership with EVI but also expands its contributions to innovative vaccine development strategies.

As the global health landscape continues to evolve, initiatives like this one underscore the collaboration between public and private sectors in addressing pressing health challenges. By enhancing the tools available for influenza research, the partnership aims to improve seasonal vaccine effectiveness and ultimately safeguard public health. The collaboration between Naobios, Nuvonis, and EVI represents a significant step forward in the ongoing fight against influenza.